A phase 2 trial (RESCUE, NCT03926117) evaluated the effect of IL-6 inhibitor, ziltivekimab on the percentage change of high-sensitivity CRP in adult patients with moderate to severe CKD and high-sensitivity CRP of at least 2 mg/L.311 After 12 weeks, ziltivekimab reduced the levels of high-sensitivity CRP significantly in a dose-dependent way. Here, CRP is linked to chronic kidney disease.